Evaluation of the frequency of TP53 gene codon 72 polymorphisms in Iranian patients with endometrial cancer

Cancer Genetics and Cytogenetics

Volumn 196, Issue 2, 2010, Pages 167-170

  Ghasemi, Nasrin ^a   Karimi Zarchi, Mojgan ^a   Mortazavi Zadeh, Mohammad Reza ^a   Atash Afza, Ali ^a  

^a SHAHID SADOUGHI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; PROLINE; PROTEIN P53;

ADULT; AGED; ALLELE; APOPTOSIS; ARTICLE; CANCER RISK; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; DNA DETERMINATION; ENDOMETRIUM CANCER; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; IRAN; POPULATION RESEARCH; PRIORITY JOURNAL;

ADULT; AGED; ARGININE; BASE SEQUENCE; CASE-CONTROL STUDIES; CODON; DNA PRIMERS; ENDOMETRIAL NEOPLASMS; FEMALE; GENES, P53; HUMANS; IRAN; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROLINE;

EID: 71949119495     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2009.09.013     Document Type: Article

References (35)

1. Dulić V., Kaufmann W.K., Wilson S.J., Tlsty T.D., Lees E., Harper J.W., Elledge S.J., and Reed S.I. P53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76 (1994) 1013-1023
2. Woods D.B., and Vousden K.H. Regulation of p53 function. Exp Cell Res 264 (2001) 56-66
3. Greenblatt M.S., Bennett W.P., Hollstein M., and Harris C.C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54 (1994) 4855-4878
4. Johnson T.M., Meade K., Pathak N., Marques M.R., and Attardi L.D. Knockin mice expressing a chimeric p53 protein reveal mechanistic differences in how p53 triggers apoptosis and senescence. Proc Natl Acad Sci U S A 105 (2008) 1215-1220
5. Vousden K.H., and Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2 (2002) 594-604
6. Sengupta S., and Harris C.C. p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol 6 (2005) 44-55
7. Ara S., Lee P.S., Hansen M.F., and Saya H. Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res 18 (1990) 4961
8. Siddique M., and Sabapathy K. Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene 25 (2006) 3489-3500
9. Papadakis E.D., Soulitzis N., and Spandidos D.A. Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes. Br J Cancer 87 (2002) 1013-1018
10. Bergamaschi D., Samuels Y., Sullivan A., Zvelebil M., Breyssens H., Bisso A., Del Sal G., Syed N., Smith P., Gasco M., Crook T., and Lu X. iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet 38 (2006) 1133-1141
11. Buyru N., Tigli H., and Dalay N. P53 codon 72 polymorphism in breast cancer. Oncol Rep 10 (2003) 711-714
12. Huang X.E., Hamajima N., Katsuda N., Matsuo K., Hirose K., Mizutani M., Iwata H., Miura S., Xiang J., Tokudome S., and Tajima K. Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. Breast Cancer 10 (2003) 307-311
13. Suspitsin E.N., Buslov K.G., Grigoriev M.Y., Ishutkina J.G., Ulibina J.M., Gorodinskaya V.M., Pozharisski K.M., Berstein L.M., Hanson K.P., Togo A.V., and Imyanitov E.N. Evidence against involvement of p53 polymorphism in breast cancer predisposition. Int J Cancer 103 (2003) 431-433
14. Vieira J.O., da Silva I.D., Higo P.E., Nogueira-de-Souza N.C., and Gebrim L.H. Study of p53 codon 72 polymorphism in patients with breast cancer. Eur J Gynaecol Oncol 29 (2008) 364-367
15. Khadang B., Fattahi M.J., Talei A., Dehaghani A.S., and Ghaderi A. Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women. Cancer Genet Cytogenet 173 (2007) 38-42
16. Bhattacharya P., and Sengupta S. Lack of evidence that proline homozygosity at codon 72 of p53 and rare arginine allele at codon 31 of p21, jointly mediate cervical cancer susceptibility among Indian women. Gynecol Oncol 99 (2005) 176-182
17. Saranath D., Khan Z., Tandle A.T., Dedhia P., Sharma B., Contractor R., Shrivastava S., and Dinshaw K. HPV16/18 prevalence in cervical lesions/cancers and p53 genotypes in cervical cancer patients from India. Gynecol Oncol 86 (2002) 157-162
18. Själander A., Birgander R., Saha N., Beckman L., and Beckman G. p53 polymorphisms and haplotypes show distinct differences between major ethnic groups. Hum Hered 46 (1996) 41-48
19. Khaliq S., Hameed A., Khaliq T., Ayub Q., Qamar R., Mohyuddin A., Mazhar K., and Qasim-Mehdi S. P53 mutations, polymorphisms, and haplotypes in Pakistani ethnic groups and breast cancer patients. Genet Test 4 (2000) 23-29
20. Esteller M., García A., Martínez-Palones J.M., Xercavins J., and Reventós J. Susceptibility to endometrial cancer: influence of allelism at p53, glutathione S-transferase (GSTM1 and GSTT1) and cytochrome P-450 (CYP1A1) loci. Br J Cancer 75 (1997) 1385-1388
21. Peller S., Halperin R., Schneider D., Kopilova Y., and Rotter V. Polymorphisms of the p53 gene in women with ovarian or endometrial carcinoma. Oncol Rep 6 (1999) 193-197
22. Honda T., Kato H., Imamura T., Gima T., Nishida J., Sasaki M., Hoshi K., Sato A., and Wake N. Involvement of p53 gene mutations in human endometrial carcinomas. Int J Cancer 53 (1993) 963-967
23. Kihana T., Hamada K., Inoue Y., Yano N., Iketani H., Murao S., Ukita M., and Matsuura S. Mutation and allelic loss of the p53 gene in endometrial carcinoma: incidence and outcome in 92 surgical patients. Cancer 76 (1995) 72-78
24. Ueda M., Terai Y., Kanda K., Kanemura M., Takehara M., Yamaguchi H., Nishiyama K., Yasuda M., and Ueki M. Germline polymorphism of p53 codon 72 in gynecological cancer. Gynecol Oncol 100 (2006) 173-178
25. Roh J.W., Kim J.W., Park N.H., Song Y.S., Park I.A., Park S.Y., Kang S.B., and Lee H.P. p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer. Gynecol Oncol 93 (2004) 499-505
26. Bansal N., Yendluri V., and Wenham R.M. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control 16 (2009) 8-13
27. Hashimoto H., Kojima A., Sudo T., Ohki N., Yamaguchi S., Mikami Y., Ito M., and Nishimura R. Establishment and characterization of a human cell line derived from a uterine papillary serous carcinoma with wild-type p53 function. Hum Cell 21 (2008) 64-69
28. Llobet D., Pallarés J., Yeramian A., Santacana M., Eritja N., Velasco A., Dolcet X., and Matias-Guiu X. Molecular pathology of endometrial carcinoma: practical aspects from the diagnostic and therapeutical view points. J Clin Pathol 62 (2009) 777-785
29. Zehbe I., Voglino G., Wilander E., Genta F., and Tommasino M. Codon 72 polymorphism of p53 and its association with cervical cancer. Lancet 354 (1999) 218-219
30. Sullivan A., Syed N., Gasco M., Bergamaschi D., Trigiante G., Attard M., Hiller L., Farrell P.J., Smith P., Lu X., and Crook T. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 23 (2004) 3328-3337
31. Dumont P., Leu J.I., Della Pietra III A.C., George D.L., and Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33 (2003) 357-365
32. Pim D., and Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 108 (2004) 196-199
33. Reliene R., Bishop A.J., and Schiestl R.H. Involvement of homologous recombination in carcinogenesis. Adv Genet 58 (2007) 67-87
34. Bereir R.E., Mohamed H.S., Seielstad M., El Hassani A.M., Khalil E.A., Peacock C.S., Blackwell J.M., and Ibrahim M.E. Allele frequency and genotype distribution of polymorphisms within disease-related genes is influenced by ethnic population sub-structuring in Sudan. Genetica 119 (2003) 57-63
35. Nagai M.A., Schaer Barbosa H., Zago M.A., Araújo Silva Jr. W., Nishimoto I.N., Salaorni S., Guerreiro Costa L.N., Silva Araújo M., Caldas Oliveira A.G., Mourâo Neto M., and Brentani M.M. TP53 mutations in primary breast carcinomas from white and African-Brazilian patients. Int J Oncol 23 (2003) 189-196